Immunotherapy of Melanoma With Tumor Antigen RNA and Small Inhibitory RNA Transfected Autologous Dendritic Cells

• Register: ClinicalTrials.gov
• Last refreshed on: 17 October 2012
• Main ID: NCT00672542
• Date of registration: 03/02/2008
• Primary sponsor: Duke University
• Public title: Immunotherapy of Melanoma With Tumor Antigen RNA and Small Inhibitory RNA Transfected Autologous Dendritic Cells
• Scientific title: Phase I Study of Active Immunotherapy of Metastatic Melanoma With Mature Autologous Dendritic Cells Transfected With Tumor Antigen RNA and Small Inhibitory RNAs to Alter Proteasomal Antigen Processing
• Date of first enrolment: January 2008
• Target sample size: 13
• Recruitment status: Active, not recruiting
• URL: http://clinicaltrials.gov/show/NCT00672542
• Study type: Interventional
• Study design: Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Countries of recruitment

United States

Contacts

• Name: Scott K Pruitt, MD, PhD
• Affiliation: Duke University

Key inclusion & exclusion criteria

Inclusion Criteria:

- Patients with confirmed metastatic melanoma.

- Karnofsky performance status greater than or equal to 70%.

- Estimated life expectancy > 6 months.

- Age > 18 years.

- Adequate hematologic function

- Adequate renal and hepatic function

- Ability to understand and provide signed informed consent that fulfills Institutional
Review Board guidelines.

- Ability to return to Duke University Medical Center for adequate follow-up as
required by this protocol.

Exclusion Criteria:

- Subjects undergoing concurrent chemotherapy, radiation therapy, or immunotherapy will
be excluded.

- The subject has previously irradiated, surgically treated, or newly diagnosed central
nervous system (CNS) metastases will be excluded (Pre-enrollment head CT is not
required if not indicated by clinical signs or symptoms).

- Subjects with a history of autoimmune disease such as, but not restricted to,
inflammatory bowel disease, systemic lupus erythematosus, ankylosing spondylitis,
scleroderma, or multiple sclerosis will be excluded.

- Subjects with serious concurrent chronic or acute illness such as pulmonary (asthma
or COPD), cardiac (NYHA class III or IV) or hepatic disease, or other illness
considered by the principal investigator to constitute an unwarranted high risk for
investigational drug administration will be excluded.

- Subjects with medical or psychological impediment to probable compliance with the
protocol will be excluded.

- Subjects with concurrent second malignancy other than melanoma or non-melanoma skin
cancer will be excluded. In the event of prior non-melanoma malignancies treated
surgically, the subject must be considered NED (no evidence of disease) for a minimum
of 3 years prior to enrollment.

- Presence of an active acute or chronic infection, including symptomatic urinary tract
infection, HIV (as determined by ELISA and confirmed by Western Blot) or viral
hepatitis (as determined by HBsAg and Hepatitis C serology) will lead to subject
exclusion.

- Subjects receiving steroid therapy (or other immunosuppressive agents such as
azathioprine or cyclosporine A) are excluded on the basis of potential immune
suppression.

- Subjects with inadequate peripheral vein access to undergo leukapheresis will be
excluded.

- Female subjects with a positive pregnancy test, as well as those who have not
previously undergone hysterectomy and/or bilateral oophorectomy and are unwilling to
utilize a medically approved form of contraception, from the time of enrollment until
6 weeks after the final immunization, will be excluded.

- Male subjects, not previously surgically sterilized, who are unwilling to use a
condom with spermicide during any sexual activity occurring over the entire
immunization period and for the 6 weeks that immediately follow the final
immunization will be excluded.

- Subjects with a documented history of severe allergic reaction to beta-lactams, eggs
or soy products.



Age minimum: 18 Years
Age maximum: N/A
Gender: Both

Health Condition(s) or Problem(s) studied

Absence of CNS Metastases

Metastatic Melanoma

Intervention(s)

Biological: Proteasome siRNA and tumor antigen RNA-transfected dendritic cells

Primary Outcome(s)

For this Phase I study, subjects will be evaluated both clinically and with laboratory testing for any signs of toxicity associated with vaccination. [Time Frame: 3 months after last vaccination]

Secondary Outcome(s)

For each subject, clinical responses to vaccination will also be assessed. [Time Frame: At least 3 months, and up to 5 years]

For each subject, the induction of anti-melanoma immune responses will be assessed by in vitro testing. [Time Frame: At least 3 months after final vaccination]

Secondary ID(s)

IND # BB-13545

NIH OBA # 0708-874

Pro00000806

Source(s) of Monetary Support

Please refer to primary and secondary sponsors